Navigation Links
Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
Date:1/13/2009

UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of molecular interaction analysis tools, and Uppsala University (Sweden). The collaboration combines Beactica's unique approach to fragment-based drug discovery and GE Healthcare's Biacore(TM) technology with enzymology expertise from Uppsala University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/333930 )

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit http://www.beactica.com.

For further information, please contact Dr Per Kallblad, CEO Beactica, +46(0)18-560880.


'/>"/>
SOURCE Beactica AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
4. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
5. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
6. ProUroCare Medical Inc. Announces Pricing of Equity Offering
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
9. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):